

# Kamlesh Sodani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9330370/publications.pdf>

Version: 2024-02-01

24  
papers

1,371  
citations

448610

19  
h-index

685536

24  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1905  
citing authors

#	ARTICLE	IF	CITATIONS
1	Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. <i>Pharmacological Research</i> , 2017, 121, 184-193.	3.1	13
2	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. <i>Journal of Biomedical Research</i> , 2016, 30, 120-133.	0.7	13
3	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. <i>Oncotarget</i> , 2015, 6, 510-521.	0.8	28
4	WHI 6154 enhances the chemotherapeutic effect of anticancer agents in ABCG2 overexpressing cells. <i>Cancer Science</i> , 2014, 105, 1071-1078.	1.7	21
5	Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10 Mediated Paclitaxel Resistance: A Preclinical Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 714-723.	1.9	39
6	PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. <i>Acta Pharmaceutica Sinica B</i> , 2014, 4, 202-207.	5.7	24
7	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2014, 89, 52-61.	2.0	47
8	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. <i>Oncology Reports</i> , 2014, 31, 1605-1612.	1.2	26
9	Î²-elemene, a compound derived from <i>Rhizoma zedoariae</i> , reverses multidrug resistance mediated by the ABCB1 transporter. <i>Oncology Reports</i> , 2014, 31, 858-866.	1.2	47
10	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. <i>Journal of Cancer Research Updates</i> , 2014, 3, 169-173.	0.3	1
11	Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2013, 132, 224-235.	2.3	37
12	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 189-199.	1.1	48
13	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. <i>Cancer Letters</i> , 2013, 328, 307-317.	3.2	106
14	Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. <i>PLoS ONE</i> , 2013, 8, e55576.	1.1	34
15	BBA, a Synthetic Derivative of 23-hydroxybutulinic Acid, Reverses Multidrug Resistance by Inhibiting the Efflux Activity of MRP7 (ABCC10). <i>PLoS ONE</i> , 2013, 8, e74573.	1.1	13
16	Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7268-7271.	1.0	18
17	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. <i>Biochemical Pharmacology</i> , 2012, 84, 766-774.	2.0	22
18	BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistance <i>in Vitro</i> and <i>In Vivo</i> . <i>Molecular Pharmaceutics</i> , 2012, 9, 3147-3159.	2.3	43

#	ARTICLE	IF	CITATIONS
19	Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer, 2012, 31, 58-72.	4.9	217
20	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochemical Pharmacology, 2012, 83, 1613-1622.	2.0	62
21	<sc>PDE</sc>5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (<sc>ATP</sc>-binding Cassette <sc>C</sc>10) transporter. Cancer Science, 2012, 103, 1531-1537.	1.7	37
22	Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 570-594.	0.9	185
23	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical Pharmacology, 2010, 79, 154-161.	2.0	89
24	Nilotinib (AMN107, Tasigna®) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochemical Pharmacology, 2009, 78, 153-161.	2.0	201